Rise and Shine: What you need to know before the ASX opens
Link copied to
On Stockhead today, two experts give their view on COVID-19’s impact on globalisation and Australia’s relationship with the rest of the world, the pandemic hasn’t held back Australia’s resources cash cow and can listed Aussie drug makers survive COVID-19?
Key events in Australia will be led by the RBA’s quarterly Statement on Monetary Policy (11:30am EST), where markets will be watching closely for what changes the bank will make to its central economic forecasts in the wake of COVID-19.
Looking abroad, all eyes will be on US employment data to end the week. The median forecast is for more than 20 million jobs to be lost in April, which would send US unemployment above 16 per cent.
The following companies are in trading halts and are expected to exit in the next two trading days:
Scorpion Minerals (ASX:SCN) – capital raising
RhinoMed (ASX:RNO) – capital raising
TNT Mines (ASX:TNT) – acquisition of uranium project
Exore Resources (ASX:ERX) – parting with minority interests
Sacgasco (ASX:SGC) – capital raising
ArchTIS (ASX:AR9) – capital raising
MGC Pharmaceuticals (ASX:MXC) – distribution agreement
Cellmid (ASX:CDY) – media article response
Gold: $US1,715.95 ($2,628.56) (+1.70%)
Silver: $US15.34 (+3.08%)
Oil (WTI): $US23.44 (-2.29%)
Oil (Brent): $US29.41 (-1.04%)
Coal: $US54.25 (+0.93%)
Iron 62pc Fe: $US83.29 (+0.28%)
AUD/USD: $US0.6495 (+1.48%)
Bitcoin: $US9,762.26 (+5.50%)
Rachel Williamson’s analysis of what it takes to build a successful listed medtech company — including a review of four ASX small-caps — got plenty of attention from our readers yesterday.
Also, be sure to check in at 10.20am each morning for our daily 10 at 10 column — a live summary of winners & losers at the opening bell.
These were the most tipped stocks (weekly) in Stocks in Play: